These findings indicated a possible role of increased activation of the PI3K/Akt/mTOR pathway in the chemotherapy resistance observed in our resistant BL cells suggesting that targeting this pathway may be therapeutically relevant in BL. Here, AKT1 is linked to Burkitt lymphoma.